Article
Coronary artery disease in diabetes: Which (if any) test is best?
Until randomized trials are done, the optimal testing strategy in patients with diabetes will remain subject to lively inferential debate.
Reviews
Diabetes and coronary artery disease: The role of stress myocardial perfusion imaging
Cleveland Clinic Journal of Medicine. 2005 January;72(1):21-24, 29-33
Author and Disclosure Information
Frans J. TH. Wackers, MD
Professor of Diagnostic Radiology and Medicine; Director, Cardiovascular Nuclear Imaging and Exercise Laboratories; Yale University School of Medicine, New Haven, CT
Address: Frans J. Th. Wackers, MD, Director, Cardiovascular Nuclear Imaging and Exercise Laboratories, Yale University School of Medicine, 333 Cedar Street, FMP 3, PO Box 208042, New Haven, CT 06520-8042; e-mail frans.wackers@yale.edu
The author has indicated that he is on the speakers’ bureaus of Amersham and Bristol-Myers Squibb Medical Imaging, is a consultant for King Pharmaceuticals, and has received grant or research support from Bristol-Myers Squibb Medical Imaging and Fujisawa.
This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.
ABSTRACTStress myocardial perfusion imaging (MPI) has the potential not only to improve clinical outcomes in diabetic patients, but also to decrease unnecessary use of health care resources. However, before routine screening can be recommended, cost-effectiveness analyses are required to identify patients in whom such testing is appropriate. Nevertheless, MPI is clearly emerging as a valuable tool for improving management of coronary artery disease in all patients with diabetes mellitus.